1. Home
  2. AIRT vs CTSO Comparison

AIRT vs CTSO Comparison

Compare AIRT & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air T Inc.

AIRT

Air T Inc.

HOLD

Current Price

$21.00

Market Cap

63.1M

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

N/A

Current Price

$0.80

Market Cap

45.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIRT
CTSO
Founded
1980
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.1M
45.7M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
AIRT
CTSO
Price
$21.00
$0.80
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
1.6K
67.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,503,908.00
Revenue This Year
N/A
$7.29
Revenue Next Year
N/A
$8.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
48.53
52 Week Low
$14.56
$0.60
52 Week High
$26.70
$1.39

Technical Indicators

Market Signals
Indicator
AIRT
CTSO
Relative Strength Index (RSI) 39.79 61.97
Support Level $18.38 $0.61
Resistance Level $24.74 $0.84
Average True Range (ATR) 0.50 0.04
MACD -0.32 0.01
Stochastic Oscillator 18.79 75.78

Price Performance

Historical Comparison
AIRT
CTSO

About AIRT Air T Inc.

Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: